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Abstract
Summary The treatment of 300-mg/day isoflavones (agly-
cone equivalents) (172.5 mg genistein+127.5 mg daidzein)
for 2 years failed to prevent lumbar spine and total
proximal femur bone mineral density (BMD) from declin-
ing as compared with the placebo group in a randomized,
double-blind, two-arm designed study enrolling 431 post-
menopausal women 45–65 years old.
Introduction This study evaluated the effects of soy isofla-
vones on bone metabolism in postmenopausal women.
Methods Four hundred and thirty-one women, aged 45–
65 years, orally consumed 300-mg/day isoflavones (aglycone
equivalents) or a placebo for 2 years in a parallel group,
randomized,double-blind,two-arm study.Eachparticipantalso
ingested 600 mg of calcium and 125 IU of vitamin D3 per day.
The BMD of the lumbar spine and total proximal femur were
measured using dual-energy X-ray absorptiometry at baseline
and every half-year thereafter. Serum bone-specific alkaline
phosphatase, urinary N-telopeptide of type 1 collagen/creati-
nine, and other safety assessments were examined regularly.
Results Two hundred out of 217 subjects in the isoflavone
group and 199 out of 214 cases in placebo group completed the
treatment. Serum concentrations of isoflavone metabolites,
genistein and daidzein, of the intervention group were
remarkably elevated following intake of isoflavones (p<
0.001). However, differences in the mean percentage changes
of BMD throughout the treatment period were not statistically
significant (lumbar spine, p=0.42; total femur, p=0.39)
between the isoflavone and placebo groups, according to the
generalized estimating equation (GEE) method. A significant
time trend of bone loss was observed at both sites as assessed
by the GEE method following repeated measurement of
BMD (p<0.001). Differences in bone marker levels were not
significant between the two treatment groups.
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Introduction
Estrogendeficiencyisregardedasaleadingcauseofboneloss
and osteoporosis in postmenopausal women. Although
hormone therapy (HT) in postmenopausal women has been
found to be efficacious in mitigating bone loss and preventing
bonefractures[1, 2], the results of the recent Women’sH e a l t h
Initiative trial suggest that a combination of estrogen plus
progestin taken for more than 5 years may increase the risk
of invasive breast cancer and cardiovascular events, includ-
ing coronary heart disease and stroke [3]. A trial using an
estrogen-only arm in hysterectomized women also demon-
strated a higher risk of cerebrovascular events [4]. Phytoes-
trogens exhibit weak estrogenic activity, on the order of
10
−2–10
−3 that of 17 β-estradiol [5, 6]. The three major
chemical types of phytoestrogens that have been identified
are isoflavones, lignans, and coumestans. The primary
isoflavones in aglycone form are genistein, daidzein, and
glycitein. They are found in soybeans and have been
considered by some, but not all, researchers as potential
alternatives to HT [7]. When the study was first planned in
mid-2003, many investigations evaluating the effects of
isoflavone-containing soy protein or isolated isoflavones on
bone health of peri-menopausal or postmenopausal women
had already been published. Only a few of those studies were
double-blind, randomized, placebo-controlled trials [8–12].
They were characterized by small sample size (≦175 cases),
short-term duration (≦12 months), and low daily dose
(≦99 mg aglycone equivalents). The parameters observed
were bone mineral density (BMD) and/or bone turnover
markers, and the results were inconsistent. In an attempt to
better understand the effects of soy isoflavones on bone
health, this study was designed to examine the effects of soy
isoflavones on BMD of Taiwanese postmenopausal women
with bone loss, employing a larger sample size, a higher dose
of isoflavone, and a follow-up of longer duration.
Methods
Study design
This study was designed as a 2-year, parallel group,
placebo-controlled, double-blind, two-arm clinical trial
conducted simultaneously at three medical centers in
Taiwan: the National Taiwan University Hospital (NTUH),
Changhua Christian Hospital (CCH), and National Cheng
Kung University Hospital (NCKUH). Each center has
recruited 144, 142, and 145 participants, respectively.
Because previous studies indicated that an intake of 40-g/
day soy protein containing 90-mg isoflavones for 6 months
increased lumbar spine BMD by 2.2% [8] and 54-mg
genistein/day for 12 months induced a 3% gain in BMD at
proximal femur and spine [10], it was postulated that with a
standard deviation of 4.0% in the distribution of treatment
responses, 50 participants per arm could reach over 80%
statistical power to detect a 2.5% difference in mean
percentage change in BMD in lumbar spine between the
treatment and placebo groups (with a significance level of
5%). We anticipated a 20% dropout rate, recruiting no fewer
than 140 subjects at each center.
Inclusion criteria of participants
We enrolled 431 Taiwanese postmenopausal women with
the following criteria: aged >45 and <65 years; cessation of
menses for at least 12 months and less than 10 years;
lumbar spine at second, third, and fourth lumbar vertebrae
(L2–L4) BMD 1 SD below the young adult female mean
value (T-score<−1); BMI 18.5–30 kg/m
2; follicle-
stimulating hormone (FSH) >40 IU/L; and estradiol (E2)
<40 pg/mL. The exclusion criteria were clinical or
laboratory evidence of systemic disease; presence or history
of vertebral, hip, or wrist fractures; other metabolic bone
diseases; gynecological cancer; breast cancer; cervical
smear result of class III or IV based on the Bethesda
system; undiagnosed vaginal bleeding; significant or
pathological endometrial hyperplasia; known cardiovascu-
lar, cerebrovascular, or peripheral vascular disorder; poorly
controlled diabetes with HbA1c ≥10%; uncontrolled hyper-
tension with blood pressure ≥180/100 mmHg; uncontrolled
hypothyroidism; abnormal liver function with alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) values >2-fold upper limits, or renal disease with
serum creatinine >2 mg/dL; the use of HT, selective
estrogen receptor modulators, or phytoestrogen treatment
within the previous 3 months; the use of fluoride,
calcitonin, chronic systemic corticosteroid, or any other
treatment affecting BMD within the previous 6 months; or
any use of bisphosphonate within the previous 12 months,
or an accumulative usage of any bisphosphonate for more
than 3 months before the previous 12 months (the only
available bisphosphonate in Taiwan is weekly alendronate).
For those who had undergone hysterectomy, the age had to
have been 50 to 60 years, with FSH and E2 concentrations
as previously stated. All eligible healthy postmenopausal
women were recruited between December 2004 and
January 2006. They provided written informed consent
1572 Osteoporos Int (2012) 23:1571–1580prior to participation in this study. The study protocol was
approved by local and national ethics committees in
accordance with the Declaration of Helsinki and Good
Clinical Practices Guidelines. Based upon the reports of
poor effect of daily doses of 118 [13], 150 [14] and 114 mg
[15] of isoflavone for alleviating postmenopausal vasomo-
tor symptoms, and the possibility that inquiring about hot
flash symptomatology might increase the withdrawal rate,
hot flash data were not collected in this study.
Allocation of participants
Eight hundred thirty-seven potentially eligible women
w e r ei n v i t e dt ou n d e r g ot h es c r e e n i n ge x a m i n a t i o n s .
Among the 435 eligible cases, 431 cases were random-
ized into the isoflavone treatment group or the placebo
group (Fig. 1). We obtained a randomization code for each
participant using the permuted randomization method with
a block size of eight within each center. For each center,
random codes for isoflavone or placebo were evenly
generated. Each randomization number was assigned to
an individual subject according to the time sequence of the
subject becoming eligible. Each eligible case was ran-
domized to one of the two treatment groups in a 1:1 ratio
according to a randomization list. An identification
number was not re-allocated, if the subject was withdrawn
from the study.
Study products
Each isoflavone capsule contained 50 mg of isoflavones
(aglycone equivalents) of which genistein and daidzein
comprised 57.5% and 42.5%, respectively, as evidenced by
high performance liquid chromatography (HPLC) analysis,
and the other components were microcrystalline cellulose,
xylitol, and caramel. Each subject in the isoflavone group
took three capsules of isoflavones twice a day. The
remaining subjects took three placebo capsules twice a
day. Each placebo capsule contained microcrystalline
cellulose, xylitol, caramel, and soybean sauce flavor
without isoflavones. The net weight of the content inside
each capsule was 280 mg. The exterior of the isoflavone
and placebo capsules appeared identical, and the capsules
were distributed to each participant in a double-blind
fashion. All participants also took a single calcium
phosphate tablet, containing 300 mg of elemental calcium
and 62.5 IU of vitamin D3 twice daily (Bio-cal®, TTY Co.
Ltd, Taipei, Taiwan).
Laboratory tests and questionnaires
After an overnight fast, venous blood was sampled to
determine HbA1c, plasma glucose, total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein
cholesterol, triglyceride, high sensitivity C-reactive protein,
urea nitrogen, creatinine, uric acid, ALT, and AST at
baseline and 4, 48, and 96 weeks. Serum bone-specific
alkaline phosphatase (BAP, Beckman Access Ostase®,
Fullerton, CA, USA; interassay coefficient of variation
(CV)=14% and intraassay CV=9%) and urine collected for
routine urinalysis and N-telopeptide of type 1 collagen
(NTx, Vitros Immunodiagnostic Products, Ortho-Clinical
Diagnostics, Buckinghamshire, UK; interassay CV=15%
and intraassay CV=10%) were examined at baseline and 48
and 96 weeks. Serum concentrations of isoflavone metab-
olites, genistein and daidzein, were analyzed at baseline and
48 and 96 weeks by HPLC in accordance with Franke et al.
[16]. All biochemical assays were conducted at the certified
laboratory of NTUH, except routine urinalysis at the local
hospital by the staff blinded to case and placebo status.
After randomization, the International Physical Activity
Questionnaire-Short Form [17, 18], 24-h diet recall, and the
Isoflavone Basic Diet Information Food Frequency Ques-
tionnaire [19, 20] were used to interview all participants at
baseline and 48 and 96 weeks. Participants were requested
to maintain their habitual diet and exercise patterns, which
were documented by the same dietitians based on validated
Isoflavone
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Fig. 1 Enrollment flow chart of patients. Superscript a National
Taiwan University Hospital is abbreviated as NTUH, Changhua
Christian Hospital as CCH, and National Cheng Kung University
Hospital as NCKUH. Superscript b AE denotes adverse events
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measure blood 25-hydroxyvitamin D [25(OH)D] level in
this study.
Bone mineral density assessment
Lumbar spine (L2–L4) and right total proximal femur BMD
were measured by dual-energy X-ray absorptiometry
(DXA) at baseline and 24, 48, 72, and 96 weeks after
randomization. The manufacturers of the DXA equipment
used at the three geographic sites were Norland XR-26
Mark II (Fort Atkinson, WI, USA), Hologic QDR 4500C
(Bedford, MA, USA), and GE-Lunar Prodigy (Madison,
WI, USA) for NTUH, CCH, and NCKUH, respectively.
Each instrument was subjected to a daily performance
check using its specific calibrator. The day-to-day CVs at
each site were 0.7%, 0.4%, and 0.3%, respectively. We also
used a circulating phantom to examine the reproducibility
of the three sets of instruments. The CVs of the repeated
readings (once every 4 months, N=7) were 0.7%, 0.2%,
and 0.6% for Norland, Hologic, and Lunar instruments,
respectively. The BMD of each subject was measured by
the same certified technician using the same instrument
throughout the entire study period. Because there had been
some differences in BMD among these three instruments,
the primary endpoint was used to examine the percentage
change in BMD during the course of treatment. We decided
to detect lumbar spine BMD at L2 to L4 level because of
the software limitation of Norland XR-26 Mark II. Total
proximal femur BMD data from NTUH site were also
missing due to the software limitation of the Norland XR-
26 Mark II.
Safety and adverse events
In addition to the aforementioned laboratory tests, the
safety of the participants was further monitored by
conducting mammography for occult breast cancer, gyne-
cological sonography for evaluation of endometrial thick-
ness, pap smears for cervical dysplasia or cancer, and X-
rays for vertebral fractures at baseline and 96 weeks after
randomization. Adverse events were classified according to
body system and the coding symbols for a thesaurus of
adverse reaction terms were used [21]. Participants were
asked about their symptoms at the clinics every 3 months.
Compliance
To ensure the compliance of the participants, new capsules
were distributed and unused capsules retrieved every
3 months to estimate compliance rates. The compliance
rate was calculated as the percentage of total taken capsules
in the total dispensed capsules.
Statistical methods
Descriptive data are given as the mean (standard deviation,
SD) for continuous variables and number (percent) for
categorical variables. For continuous variables, differences
in mean percentage changes from baseline between the two
groups were evaluated by Student’s t test. The primary
efficacy data on lumbar spine and total proximal femur
BMD were examined using intention-to-treat analysis.
Additionally, we used a generalized estimating equation
(GEE) model to estimate the differences in values of BMD,
BAP, and NTx/creatinine at each time point between the
two groups and also the time trend after treatment. A p
value of 0.05 or less was considered statistically significant.
Results
Baseline characteristics of study participants
The enrollment flow chart of patients is displayed in Fig. 1.
Two hundred out of 217 cases and 199 out of 214 cases,
respectively, in the isoflavone and placebo groups complet-
ed the treatment. The compliance rate was estimated at
approximately 88%. The randomization codes of 431 cases
were not broken, and unblinding did not occur in any case
until the conclusion of the study. As indicated in Table 1,n o
significant differences in terms of demographic character-
istics were observed between the two groups. There were
no significant differences detected at baseline in body
weight, daily activity, isoflavone intake, calcium intake,
total energy intake, bone turnover markers, or lumbar spine
and total femur BMD. Daily physical activity, energy
intake, and isoflavone intake showed no significant differ-
ences within or between groups at 48 and 96 weeks after
randomization.
The efficacy of isoflavone on bone
Table 2 shows the serum concentrations of genistein and
daidzein. The serum concentrations of isoflavones were
remarkably elevated in the isoflavone group (p<0.001).
Table 3 shows the mean percentage changes (95% CI) from
their corresponding baseline values for lumbar spine (L2–
L4) and total femur BMD. The differences between the
isoflavone and placebo groups were not statistically
significant at any time point according to two-sample t
tests. Using a GEE model, the differences in mean
percentage changes of BMD at lumbar spine (p=0.42)
and total femur (p=0.39) between the isoflavone and
placebo groups after controlling for time effect still depicted
no significant difference, respectively. However, there was
significant bone loss at the two sites in both treatment
1574 Osteoporos Int (2012) 23:1571–1580groups (p<0.001). In the 2-year study period, both groups
lost approximately 1.5% of spine BMD and 1.0% of total
femur BMD. Because biases may persist in pooled BMD
data from different instruments, we also analyzed mean
percentage change from baseline lumbar spine and total
femur BMD derived from each center. The result failed to
reveal any significant difference between the isoflavone and
placebo groups (Table 4). There was no statistically
significant difference in serial percentage changes of bone
markers between the two groups according to two-sample t
tests (Table 5). Again, using a GEE method, the difference in
the serial percentage changes of BAP and urinary NTx/
creatinine from their corresponding baselines failed to show
any statistical significance between the isoflavone and
placebo groups (p=0.78 and 0.43, respectively).
Bone fractures
In the isoflavone group, 15 cases were reported with
fractures of the clavicle (1 case), wrist (3 cases), ankle (2
cases), proximal femur (1 case), and vertebral bodies (8
cases), respectively, whereas there were 2 cases of wrist
fractures and 7 cases of vertebral fractures in the placebo
group. All cases with clavicle, wrist, ankle, and proximal
femur fractures except one case with colles’ fracture
were hospitalized for a period of time and continued the
clinical trial. Only the case with proximal femur fracture
withdrew, because she was treated with a bisphosphonate
following the fracture. The relative risk of bone fracture
and its 95% CI for the isoflavone group were 1.64 (0.74,
3.67).
Table 1 Demographic charac-
teristics in the isoflavone and
placebo groups
Data are mean (SD) as continu-
ous variable; number (percent)
as categorical variable. Lumbar
spine (L2–L4) and total proxi-
mal femur BMD were measured
by dual-energy X-ray absorpti-
ometry (DXA). The manufac-
turers of DXA equipment used
at the three geographic sites are
Norland XR-26 Mark II (Fort
Atkinson, WI, USA), Hologic
QDR 4500C (Bedford, MA,
USA), and GE-Lunar Prodigy
(Madison, WI, USA) for NTUH,
CCH, and NCKUH, respectively
ap value indicates difference
between the isoflavone and pla-
cebo groups assessed by two-
sample t test
bThere were 145 participants in
the isoflavone group and 142
participants in the placebo group
BMD bone mineral density,
METs metabolic equivalents
Isoflavone (N=217) Placebo (N=214) p value
a
Mean (SD) or number (%) Mean (SD) or number (%)
Age (years) 55.8 (3.6) 55.9 (4.0) 0.16
Weight (kg) 54.9 (5.9) 54.5 (7.2) 0.51
Body mass index (kg/m
2) 23.0 (2.4) 22.8 (2.8) 0.42
Menopausal duration (years) 5.0 (2.7) 5.1 (2.6) 0.59
History of hysterectomy
Yes 28 (13%) 24 (11%) 0.59
Cigarette smoking
Past 1 0
Habitual alcohol consumption
Yes 6 (3%) 7 (3%) 0.88
History of diabetes
Yes 17 (8%) 16 (7%) 0.89
History of hypertension
Yes 35 (16%) 38 (18%) 0.65
History of hyperlipidemia
Yes 108 (50%) 96 (45%) 0.31
Lumbar spine BMD (g/cm
2)
NTUH 0.808 (0.081) 0.815 (0.095) 0.63
CCH 0.860 (0.082) 0.865 (0.077) 0.74
NCKUH 0.920 (0.081) 0.918 (0.072) 0.92
Total proximal femur BMD
b (g/cm
2)
CCH 0.795 (0.084) 0.772 (0.089) 0.12
NCKUH 0.832 (0.082) 0.827 (0.105) 0.71
Bone alkaline phosphatase (μg/L) 15.96 (5.58) 16.41 (5.83) 0.42
Urinary N-telopeptide of type 1
collagen/creatinine (nM BCE/
mM)
62.12 (29.10) 67.29 (45.25) 0.17
Daily physical activity (total METs/
week)
4,364 (2,287) 4,320 (2,268) 0.85
Daily isoflavone intake (mg) 23 (21) 25 (28) 0.37
Daily energy intake (kcal) 1,535 (502) 1,547 (512) 0.82
Daily calcium intake (mg) 538 (340) 508 (367) 0.11
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With the exception of the fractures mentioned above over
the 2-year course of treatment, those cases marked by
withdrawal of agreement, failure to be reached during
follow-up, and protocol violation are listed in Fig. 1.
Additionally, one case in the isoflavone arm had a skin
reaction (itching) and discontinued the study. The overall
incidence rate of adverse events was not significantly
different between the two groups.
Serious adverse events
Six serious adverse events occurred in the placebo group
throughout the course (one acute myocardial infarction, one
intracerebral hemorrhage, one transient ischemic attack, one
head injury, and two cases of colon cancer). In the isoflavone
group, one case was admitted for blood pressure control and
another case underwent surgery for breast cancer. The overall
incidence rate of serious adverse events was not significantly
different between the two arms.
Discussion
The results of the current randomized, double-blind,
placebo-controlled study indicated that a daily intake of
300-mg isoflavones (aglycone equivalents) for 2 years
generated no difference in the rate of bone loss at the
lumbar spine or total femur. The two bone turnover markers
examined, serum BAP and urinary NTx/creatinine, similar-
ly showed no significant difference between the two groups
throughout the course of treatment. In terms of time trend,
isoflavone treatment in this study failed to change bone
Table 2 Mean (SD) of serum
genistein and daidzein concen-
trations at each visit
p value indicates difference be-
tween the isoflavone and place-
bo groups assessed by two-
sample t test
Variable and group Baseline (N) 4 weeks (N) 48 weeks (N) 96 weeks (N)
Genistein (μ mol/L)
Isoflavone 0.34 (1.26) (212) 6.85 (5.05) (210) 4.10 (4.34) (204) 3.30 (3.18) (200)
Placebo 0.23 (0.74) (211) 0.19 (0.71) (210) 0.20 (0.67) (203) 0.24 (0.80) (198)
Difference (95% CI) 0.11 (−0.08, 0.31) 6.66 (5.96, 7.35) 3.91 (3.30, 4.51) 3.05 (2.60, 3.51)
p value 0.80 <0.001 <0.001 <0.001
Daidzein (μ mol/L)
Isoflavone 0.09 (0.36) (212) 1.44 (1.35) (212) 1.12 (1.16) (204) 0.73 (0.92) (200)
Placebo 0.05 (0.20) (211) 0.07 (0.35) (211) 0.10 (0.48) (203) 0.04 (0.23) (199)
Difference (95% CI) 0.05 (−0.01, 0.10) 1.38 (1.19, 1.56) 1.02 (0.85, 1.19) 0.69 (0.56, 0.82)
p value 0.34 <0.001 <0.001 <0.001
Table 3 Mean percentage changes (SD) of BMD from baseline in lumbar spine and total proximal femur in the isoflavone and placebo groups at
each visit
Measurement Follow-up
(weeks)
Isoflavone Placebo Difference p value
a p value
b p value for
time trend
c Mean percentage
change (SD) (N)
Mean percentage
change (SD) (N)
Mean (95% CI)
Lumbar spine 24 0.24 (3.25) (205) −0.04 (3.14) (205) 0.27 (−0.35, 0.89) 0.38 0.42 <0.001
48 −0.29 (3.12) (202) −0.55 (3.52) (199) 0.26 (−0.39, 0.91) 0.43
72 −1.14 (3.58) (200) −0.92 (3.96) (199) −0.23 (−0.97, 0.52) 0.55
96 −1.09 (3.95) (200) −1.72 (4.12) (199) 0.63 (−0.17, 1.42) 0.12
Total proximal
femur
24 −0.02 (2.63) (136) −0.13 (2.43) (136) 0.11 (−0.49, 0.71) 0.72 0.39 <0.001
48 −0.0004 (2.93) (133) −0.40 (2.72) (133) 0.40 (−0.28, 1.08) 0.25
72 −0.13 (3.31) (129) −0.12 (3.85) (130) −0.004 (−0.88, 0.88) 0.99
96 −0.81 (3.59) (133) −1.35 (2.67) (132) 0.54 (−0.23, 1.30) 0.17
ap value denotes the comparison of mean percentage changes from respective baseline between the isoflavone and placebo groups by two-sample
t test
bp value indicates the comparison of mean percentage change from respective baseline between the isoflavone and placebo groups using the
generalized estimating equation (GEE) methods to control for time effect in the repeated measurement
cp value for time trend denotes the repeated measurement of time trend in the GEE model
BMD bone mineral density
1576 Osteoporos Int (2012) 23:1571–1580turnover biomarkers and failed to prevent lumbar spine or
total femur BMD from declining (Tables 3, 4, and 5).
Additionally, the examined serum genistein and daidzein
concentrations testified to the high compliance of partic-
ipants as well as the high bioavailability of isoflavones.
Unlike the results in this study, several previous studies
[8–12, 22, 23] and two meta-analyses [24, 25] showed a
number of beneficial effects of soy isoflavones on bone.
Most of them included only small sample sizes (≦175
subjects) and may have been biases, or short follow-up
Table 4 Mean percentage changes (SD) of BMD from baseline in lumbar spine and total proximal femur in the isoflavone and placebo groups at
each visit
Measurement Follow-up
(weeks)
Isoflavone Placebo Difference p value
a p value
b p value for
time trend
c Mean percentage
change (SD) (N)
Mean percentage
change (SD) (N)
Mean (95% CI)
Lumbar spine
NTUH 24 −0.14 (3.56) (68) −0.21 (3.40) (68) 0.07 (−1.11, 1.26) 0.90 0.65 0.001
48 −0.12 (3.58) (67) −0.22 (3.58) (66) 0.10 (−1.13, 1.32) 0.88
72 −0.96 (3.75) (66) −0.22 (4.31) (66) −0.73 (−2.12, 0.66) 0.30
96 −1.04 (4.18) (67) −1.13 (4.49) (66) 0.09 (−1.40, 1.57) 0.91
CCH 24 0.18 (3.20) (70) −0.12 (2.39) (65) 0.30 (−0.67, 1.26) 0.55 0.79 0.001
48 −0.64 (2.53) (69) −1.27 (3.12) (63) 0.63 (−0.35, 1.62) 0.21
72 −2.16 (3.02) (68) −1.64 (3.50) (63) −0.52 (−1.64, 0.61) 0.37
96 −1.81 (3.41) (68) −2.43 (3.47) (63) 0.62 (−0.57, 1.81) 0.30
NCKUH 24 0.68 (2.94) (67) 0.20 (3.50) (72) 0.48 (−0.61, 1.57) 0.39 0.62 <0.001
48 −0.08 (3.19) (66) −0.21 (3.75) (70) 0.12 (−1.06, 1.31) 0.84
72 −0.29 (3.71) (66) −0.92 (3.94) (70) 0.63 (−0.67, 1.93) 0.34
96 −0.40 (4.15) (65) −1.64 (4.26) (70) 1.24 (−0.19, 2.67) 0.09
Total proximal femur
CCH 24 −0.25 (3.12) (69) −0.32 (3.05) (64) 0.07 (−0.98, 1.13) 0.89 0.06 0.001
48 0.09 (3.65) (68) −0.79 (3.42) (63) 0.87 (−0.35, 2.10) 0.16
72 0.39 (4.16) (64) 0.004 (5.29) (60) 0.39 (−1.30, 2.07) 0.65
96 −1.10 (4.12) (68) −2.12 (2.85) (62) 1.03 (−0.19, 2.25) 0.10
NCKUH 24 0.21 (2.00) (67) 0.04 (1.70) (72) 0.17 (−0.45, 0.79) 0.59 0.71 0.001
48 −0.09 (1.92) (65) −0.05 (1.85) (70) −0.04 (−0.68, 0.60) 0.90
72 −0.63 (2.09) (65) −0.23 (1.94) (70) −0.41 (−1.09, 0.28) 0.24
96 −0.51 (2.95) (65) −0.66 (2.32) (70) 0.15 (−0.75, 1.05) 0.74
ap value denotes the comparison of percentage changes from respective baseline between the isoflavone and placebo groups by two-sample t test
bp value indicates the comparison of mean percentage change from respective baseline between the isoflavone and placebo groups using the
generalized estimating equation (GEE) methods to control for time effect in the repeated measurement
cp value for time trend denotes the repeated measurement of time trend in GEE model
BMD bone mineral density
Table 5 Mean percentage changes (SD) of serum bone alkaline phosphatase (BAP) and urinary N-telopeptide/creatinine (NTx/Cr) from baseline
in the isoflavone and placebo groups at each visit
Measurement Follow-up
(weeks)
Isoflavone Placebo Difference p value
a p value
b
Mean percentage
change (SD) (N)
Mean percentage
change (SD) (N)
Mean (95% CI)
Serum bone alkaline phosphatase
(BAP, μg/L)
48 −4.42 (29.13) (201) −3.64 (39.10) (200) −0.78 (−7.55, 5.99) 0.82 0.78
96 −1.98 (28.56) (199) −4.23 (28.82) (199) 2.24 (−3.41, 7.90) 0.44
Urinary N-telopeptide/creatinine
(NTx/Cr, nM BCE/mM)
48 12.80 (47.04) (201) 10.53 (58.71) (199) 2.26 (−8.19, 12.72) 0.67 0.43
96 9.01 (50.08) (198) 3.23 (66.22) (198) 5.77 (−5.82, 17.37) 0.33
ap value denotes the comparison of changes from respective baseline between the isoflavone and placebo groups by two-sample t test
bp value indicates the comparison of mean change from respective baseline between the isoflavone and placebo groups using the generalized
estimating equation (GEE) methods to control for time effect in the repeated measurement
BAP bone-specific alkaline phosphatase, NTx/Cr N-telopeptide/creatinine
Osteoporos Int (2012) 23:1571–1580 1577periods (≦12 months), so that true long-term effects could
not be assessed, and most of these studies did not measure
the serum levels of isoflavones. The two recent meta-
analyses (both by Taku et al.) analyzed the overall effects of
soy isoflavone supplements on bone turnover markers and
BMD separately [24, 25]. There was only a modest overall
decrease of urinary deoxypyridinoline, whereas the other
bone turnover markers including osteocalcin, BAP, and
other bone resorption markers did not show a significant
change [24]. Meta-analysis on the effects of supplementa-
tion with soy isoflavone extract with an average of 82 (47–
150) mg (aglycone equivalents) on BMD showed an
increase in lumbar spine BMD by 2.4% after 6 to
12 months. However, no significant change of proximal
femur BMD could be found [25]. Taken together, these
results were different from those of conventional estrogen
therapy, making it difficult to obtain a clear picture of the
mechanism behind the action of isoflavone, a phytoestro-
gen, on bones. On the other hand, several recent reports
have demonstrated the absence of beneficial effects of
isoflavones on bone [26–34], supporting our findings. This
controversy may be the result of differences in dosage,
product forms, length of observations, ethnic dietary habits,
or other factors. To further complicate the issue, a number
of reports have claimed antagonistic activities of various
isoflavones [35], or the need for the presence of soy protein
for isoflavones to exert their effects on BMD [8, 36, 37].
For example, Morabito et al. and Marini et al. reported that
the ingestion of single isoflavone-genistein 54 mg/day for 1
[10]a n d2y e a r s[ 23] resulted in a decline of bone
resorption markers and an increase in bone formation
markers and BMD of the lumbar spine and femoral neck.
These outcomes were totally different from ours. Because
each subject in the isoflavone arm of the current study
consumed 172.5-mg genistein and 127.5-mg daidzein/day,
whether the discrepancy between our results and those of
aforementioned authors is due to the antagonistic activities
of various isoflavones requires further clarification. We
administered a relatively large dose of a common aglycone
combination (57.5% genistein and 42.5% daidzein, without
soy protein) and measured bone turnover markers and
BMD both at the lumbar spine and proximal femur every
6 months. Our results did not show any significant effects
throughout the 24 months, in the presence of markedly
elevated serum levels of genistein and diadzein of the
isoflavone-treated group. Thus, our results strongly suggest
that soy isoflavones in the form and dosage used in this
study have no transient or long-term effect on bone in
postmenopausal women.
One of the participants in the isoflavone arm was
diagnosed with breast cancer in the study period. According
to the statistics of Taiwan Cancer Registry, Department of
Health, Executive Yuan for the year 2006, the incidence rate
of breast cancer in the entire female population aged 45–
64 years in Taiwan was 141.9/100,000 person-year, which
was apparently lower than the incidence rate of breast
cancer in the isoflavone group of this study (230.4/100,000
person-year). This subject was treated with estrogen and
progesterone for 3–4 years after menopause and discon-
tinued for more than 1 year prior to randomization in this
study. The breast cancer of this subject might be incidental,
and the causal relationship remains unclear.
This study may have shortcomings. (1) The baseline
serum levels of genistein and daidzein were higher than
those reported in the Caucasian population [31, 38], which
may mask the effects of the supplement. Nonetheless, the
baseline levels were far lower than the post-treatment levels
of the isoflavone-treated subjects, making this possibility
less likely. (2) The supplement of vitamin D (125 IU of
vitamin D3 daily) in this study may have been suboptimal.
We did not measure plasma 25(OH)D level in this study.
Consequently, the possibility of vitamin D deficiency or
insufficiency and their impact on the effects of isoflavones
could not be completely ruled out. However, all our
participants were ambulatory. A previous study on the
nutritional status of vitamin D among ambulatory women
aged 40 to 75 of Taipei City reported that vitamin D
deficiency was very rare [39], and it was further supported
by the report that dietary vitamin D intakes were relatively
adequate in this population [40]. Thus, vitamin D insuffi-
ciency or deficiency may not have been a major factor for
thelackofeffectsofisoflavones.(3)Wedidnotcollectdataon
hot flashes that could have served as a reflection of the
biological effect and the appropriateness of the dosage of
the isoflavones used in this study, in addition to the serum
levels of isoflavones. (4) We used three different models of
instruments from three different manufacturers to measure
BMD. The variations among the three instruments may
have masked the effects of soy isoflavones. However, we
performed BMD measurements according to the Interna-
tional Society of Clinical Densitometry guidelines. The
instruments had daily quality checks andwereoperatedby
the same technologists throughout the period of study. The
results within each center were analyzed separately and did
not show any trend of effects. (5) A lack of total proximal
femur BMD data from one center may have reduced the
power to estimate the effect of soy isoflavones. However, it
is difficult to perceive how isoflavone treatment could
improve proximal femur BMD while providing no benefit
in preventing bone loss at the lumbar spine. (6) Our sample
size was not sufficient to analyze the effects of soy
isoflavone on fracture rates. The fracture incidence in our
s t u d ya p p e a r e dh i g h e rt h a nt h er e s u l t sr e p o r t e db ya
prospective study in Shanghai, China [41]. It should be noted
that our study included only osteopenic or osteoporotic
women, whereas the study in Shanghai included a
1578 Osteoporos Int (2012) 23:1571–1580cohort from the general population. However, in view of
64% increase in bone fracture rate in the isoflavone arm
compared with that of the placebo arm, more cautious
monitoring in this regard is warranted in the future studies.
Conclusions
The current double-blind, randomized, placebo-controlled
study of soy-extracted isoflavones on bone health failed to
detect either an antiresorptive or a bone-sparing effect,
despite possessing the strengths of larger dose, long
observation period, and high compliance rate.
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